Skip to main content
Top
Published in: Systematic Reviews 1/2021

01-12-2021 | Opioids | Protocol

Effectiveness of interventions for prevention of common infections in people who use opioids: a protocol for a systematic review of systematic reviews

Authors: Irina Kudrina, Svetlana Puzhko, Kristian B. Filion, Genevieve Gore, Elena Paraskevopoulos, Sarah Windle, Marc O. Martel, Mark J. Eisenberg

Published in: Systematic Reviews | Issue 1/2021

Login to get access

Abstract

Background

The North American opioid crisis is driven by opioid-related mortality and morbidity, including opioid use-associated infections (OUAIs), resulting in a substantial burden for society. Users of legal and illegal opioids are at an increased risk of OUAIs compared to individuals not using opioids. As reported for hepatitis C virus (HCV), human immunodeficiency virus (HIV), bacterial, fungal, and other infections, OUAIs transmission and acquisition risks may be modifiable. Several systematic reviews (SRs) synthetized data regarding interventions to prevent infections in persons using drugs (e.g., opioid substitution therapy, needle and syringes exchange programs, psycho-social interventions); however, their conclusions varied. Therefore, SR of published SRs is needed to synthesize the highest level of evidence on the scope and effectiveness of interventions to prevent OUAIs in people using opioids legally or illegally.

Methods

We will comprehensively search for SRs in the PubMed, Embase, PsycINFO, Cochrane Database of Systematic Reviews, Epistemonikos, and Google Scholar databases from inception to November 2020. Data selection and extraction for each SR will be performed independently by two researchers, with disagreements resolved by consensus. All SRs regarding interventions with evaluated effectiveness to prevent OUAI in legal and/or illegal opioid users will be eligible. Risk of bias assessment will be performed using the AMSTAR2 tool. The results will be qualitatively synthesized, and a typology of interventions’ effectiveness with a statement on the strength of evidence for each category will be created.

Discussion

Our pilot search of PubMed resulted in 379 SRs analyzing the effectiveness of interventions to prevent HCV and HIV in persons who inject different types of drugs, including opioids. Of these 379 SRs, 8 evaluated primary studies where participants used opioids and would therefore be eligible for inclusion. The search results thus justify the application of SR of SRs approach. Comprehensive data on the scope and effectiveness of existing interventions to prevent OUAIs will help policy-makers to plan and implement preventive interventions and will assist clinicians in the guidance for their patients using opioids.

Systematic review registration

Registered in PROSPERO on 30 July 2020 (#195929).
Appendix
Available only for authorised users
Literature
1.
go back to reference Berterame S, Erthal J, Thomas J, Fellner S, Vosse B, Clare P, et al. Use of and barriers to access to opioid analgesics: a worldwide, regional, and national study. Lancet. 2016;387:1644–56.PubMedCrossRef Berterame S, Erthal J, Thomas J, Fellner S, Vosse B, Clare P, et al. Use of and barriers to access to opioid analgesics: a worldwide, regional, and national study. Lancet. 2016;387:1644–56.PubMedCrossRef
4.
go back to reference Sanger N, Bhatt M, Zielinski L, Sanger S, Shahid H, Bantoto B, et al. Treatment outcomes in patients with opioid use disorder initiated by prescription: a systematic review protocol. Syst Rev. 2018;7:16.PubMedPubMedCentralCrossRef Sanger N, Bhatt M, Zielinski L, Sanger S, Shahid H, Bantoto B, et al. Treatment outcomes in patients with opioid use disorder initiated by prescription: a systematic review protocol. Syst Rev. 2018;7:16.PubMedPubMedCentralCrossRef
5.
go back to reference Florence C, Luo F, Xu L, Zhou C. The economic burden of prescription opioid overdose, abuse and dependence in the United States, 2013. Med Care. 2016;54:901.PubMedPubMedCentralCrossRef Florence C, Luo F, Xu L, Zhou C. The economic burden of prescription opioid overdose, abuse and dependence in the United States, 2013. Med Care. 2016;54:901.PubMedPubMedCentralCrossRef
7.
go back to reference Alpren C, Dawson EL, John B, Cranston K, Panneer N, Fukuda HD, et al. Opioid use fueling HIV transmission in an urban setting: an outbreak of HIV infection among people who inject drugs—Massachusetts, 2015–2018. Am J Public Health. 2020;110:37–44.PubMedPubMedCentralCrossRef Alpren C, Dawson EL, John B, Cranston K, Panneer N, Fukuda HD, et al. Opioid use fueling HIV transmission in an urban setting: an outbreak of HIV infection among people who inject drugs—Massachusetts, 2015–2018. Am J Public Health. 2020;110:37–44.PubMedPubMedCentralCrossRef
8.
go back to reference Ko JY, Haight SC, Schillie SF, Bohm MK, Dietz PM. National trends in hepatitis C infection by opioid use disorder status among pregnant women at delivery hospitalization—United States, 2000–2015. Morb Mortal Wkly Rep. 2019;68:833.CrossRef Ko JY, Haight SC, Schillie SF, Bohm MK, Dietz PM. National trends in hepatitis C infection by opioid use disorder status among pregnant women at delivery hospitalization—United States, 2000–2015. Morb Mortal Wkly Rep. 2019;68:833.CrossRef
9.
go back to reference Sodhi N, Anis HK, Acuña AJ, Vakharia RM, Gold PA, Garbarino LJ, et al. Opioid use disorder is associated with an increased risk of infection after total joint arthroplasty: a large database study. Clin Orthop Relat Res. 2020;478:1752–9.PubMedPubMedCentralCrossRef Sodhi N, Anis HK, Acuña AJ, Vakharia RM, Gold PA, Garbarino LJ, et al. Opioid use disorder is associated with an increased risk of infection after total joint arthroplasty: a large database study. Clin Orthop Relat Res. 2020;478:1752–9.PubMedPubMedCentralCrossRef
10.
go back to reference Mora AL, Salazar M, Pablo-Caeiro J, Frost CP, Yadav Y, DuPont HL, et al. Moderate to high use of opioid analgesics are associated with an increased risk of Clostridium difficile infection. Am J Med Sci. 2012;343:277–80.PubMedCrossRef Mora AL, Salazar M, Pablo-Caeiro J, Frost CP, Yadav Y, DuPont HL, et al. Moderate to high use of opioid analgesics are associated with an increased risk of Clostridium difficile infection. Am J Med Sci. 2012;343:277–80.PubMedCrossRef
12.
go back to reference Coverdale NS, Brogly SB, Payne D, Lajkosz K, Gomes T, Abdollah H, et al. Rates of infective endocarditis in substance use disorder and associated costs in Ontario. Can J Addict. 2019;10:36–43.CrossRef Coverdale NS, Brogly SB, Payne D, Lajkosz K, Gomes T, Abdollah H, et al. Rates of infective endocarditis in substance use disorder and associated costs in Ontario. Can J Addict. 2019;10:36–43.CrossRef
13.
go back to reference Marks LR, Munigala S, Warren DK, Liang SY, Schwarz ES, Durkin MJ. Addiction medicine consultations reduce readmission rates for patients with serious infections from opioid use disorder. Clin Infect Dis. 2019;68:1935–7.PubMedCrossRef Marks LR, Munigala S, Warren DK, Liang SY, Schwarz ES, Durkin MJ. Addiction medicine consultations reduce readmission rates for patients with serious infections from opioid use disorder. Clin Infect Dis. 2019;68:1935–7.PubMedCrossRef
14.
15.
16.
go back to reference Dublin S, Walker RL, Jackson ML, Nelson JC, Weiss NS, Von Korff M, et al. Use of opioids or benzodiazepines and risk of pneumonia in older adults: a population-based case–control study. J Am Geriatr Soc. 2011;59:1899–907.PubMedPubMedCentralCrossRef Dublin S, Walker RL, Jackson ML, Nelson JC, Weiss NS, Von Korff M, et al. Use of opioids or benzodiazepines and risk of pneumonia in older adults: a population-based case–control study. J Am Geriatr Soc. 2011;59:1899–907.PubMedPubMedCentralCrossRef
17.
go back to reference Wiese AD, Griffin MR, Schaffner W, Stein CM, Greevy RA, Mitchel EF Jr, et al. Opioid analgesic use and risk for invasive pneumococcal diseases: a nested case–control study. Ann Intern Med. 2018;168:396–404.PubMedPubMedCentralCrossRef Wiese AD, Griffin MR, Schaffner W, Stein CM, Greevy RA, Mitchel EF Jr, et al. Opioid analgesic use and risk for invasive pneumococcal diseases: a nested case–control study. Ann Intern Med. 2018;168:396–404.PubMedPubMedCentralCrossRef
18.
19.
go back to reference Wiese AD, Griffin MR, Stein CM, Mitchel EF Jr, Grijalva CG. Opioid analgesics and the risk of serious infections among patients with rheumatoid arthritis: a self-controlled case series study. Arthritis Rheumatol. 2016;68:323–31.PubMedPubMedCentralCrossRef Wiese AD, Griffin MR, Stein CM, Mitchel EF Jr, Grijalva CG. Opioid analgesics and the risk of serious infections among patients with rheumatoid arthritis: a self-controlled case series study. Arthritis Rheumatol. 2016;68:323–31.PubMedPubMedCentralCrossRef
20.
go back to reference Roy S, Ninkovic J, Banerjee S, Charboneau RG, Das S, Dutta R, et al. Opioid drug abuse and modulation of immune function: consequences in the susceptibility to opportunistic infections. J Neuroimmune Pharmacol. 2011;6:442.PubMedPubMedCentralCrossRef Roy S, Ninkovic J, Banerjee S, Charboneau RG, Das S, Dutta R, et al. Opioid drug abuse and modulation of immune function: consequences in the susceptibility to opportunistic infections. J Neuroimmune Pharmacol. 2011;6:442.PubMedPubMedCentralCrossRef
21.
go back to reference Tahamtan A, Tavakoli-Yaraki M, Mokhtari-Azad T, Teymoori-Rad M, Bont L, Shokri F, et al. Opioids and viral infections: a double-edged sword. Front Microbiol. 2016;7:970.PubMedPubMedCentralCrossRef Tahamtan A, Tavakoli-Yaraki M, Mokhtari-Azad T, Teymoori-Rad M, Bont L, Shokri F, et al. Opioids and viral infections: a double-edged sword. Front Microbiol. 2016;7:970.PubMedPubMedCentralCrossRef
22.
go back to reference Integrated prevention services for HIV infection, viral hepatitis, sexually transmitted diseases, and tuberculosis for persons who use drugs illicitly: summary guidance from CDC and the U.S. Department of Health and Human Services. https://mdanderson.libanswers.com/faq/26219. Accessed 10 Aug 2020. Integrated prevention services for HIV infection, viral hepatitis, sexually transmitted diseases, and tuberculosis for persons who use drugs illicitly: summary guidance from CDC and the U.S. Department of Health and Human Services. https://​mdanderson.​libanswers.​com/​faq/​26219. Accessed 10 Aug 2020.
24.
go back to reference Worswick J, Wayne SC, Bennett R, Fiander M, Mayhew A, Weir MC, et al. Improving quality of care for persons with diabetes: an overview of systematic reviews-what does the evidence tell us? Syst Rev. 2013;2:26.PubMedPubMedCentralCrossRef Worswick J, Wayne SC, Bennett R, Fiander M, Mayhew A, Weir MC, et al. Improving quality of care for persons with diabetes: an overview of systematic reviews-what does the evidence tell us? Syst Rev. 2013;2:26.PubMedPubMedCentralCrossRef
25.
26.
go back to reference Pollock M, Fernandes RM, Becker LA, Pieper D, Hartling L. Chapter V: overviews of reviews. In: Cochrane handbook for systematic reviews of interventions version, vol. 6; 2018. Pollock M, Fernandes RM, Becker LA, Pieper D, Hartling L. Chapter V: overviews of reviews. In: Cochrane handbook for systematic reviews of interventions version, vol. 6; 2018.
27.
go back to reference Aromataris E, Fernandez R, Godfrey CM, Holly C, Khalil H, Tungpunkom P. Summarizing systematic reviews: methodological development, conduct and reporting of an umbrella review approach. Int J Evid Based Healthc. 2015;13:132–40.PubMedCrossRef Aromataris E, Fernandez R, Godfrey CM, Holly C, Khalil H, Tungpunkom P. Summarizing systematic reviews: methodological development, conduct and reporting of an umbrella review approach. Int J Evid Based Healthc. 2015;13:132–40.PubMedCrossRef
28.
go back to reference Davis SM, Daily S, Kristjansson AL, Kelley GA, Zullig K, Baus A, et al. Needle exchange programs for the prevention of hepatitis C virus infection in people who inject drugs: a systematic review with meta-analysis. Harm Reduct J. 2017;14:25.PubMedPubMedCentralCrossRef Davis SM, Daily S, Kristjansson AL, Kelley GA, Zullig K, Baus A, et al. Needle exchange programs for the prevention of hepatitis C virus infection in people who inject drugs: a systematic review with meta-analysis. Harm Reduct J. 2017;14:25.PubMedPubMedCentralCrossRef
29.
go back to reference Gowing L, Farrell MF, Bornemann R, Sullivan LE, Ali R. Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev. 2011:8:Cd004145. Gowing L, Farrell MF, Bornemann R, Sullivan LE, Ali R. Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev. 2011:8:Cd004145.
30.
go back to reference Guise A, Seguin M, Mburu G, McLean S, Grenfell P, Islam Z, et al. Integrated opioid substitution therapy and HIV care: A qualitative systematic review and synthesis of client and provider experiences. AIDS Care. 2017;29:1119–28.PubMedPubMedCentralCrossRef Guise A, Seguin M, Mburu G, McLean S, Grenfell P, Islam Z, et al. Integrated opioid substitution therapy and HIV care: A qualitative systematic review and synthesis of client and provider experiences. AIDS Care. 2017;29:1119–28.PubMedPubMedCentralCrossRef
31.
go back to reference Jarlais DCD. Systematic review research on needle/syringe programs and opiate substitution programs in low- and middle-income countries. J Food Drug Anal. 2013;21:S59–61.PubMedPubMedCentralCrossRef Jarlais DCD. Systematic review research on needle/syringe programs and opiate substitution programs in low- and middle-income countries. J Food Drug Anal. 2013;21:S59–61.PubMedPubMedCentralCrossRef
32.
go back to reference Jones L, Pickering L, Sumnall H, McVeigh J, Bellis MA. Optimal provision of needle and syringe programmes for injecting drug users: a systematic review. Int J Drug Policy. 2010;21:335–42.PubMedCrossRef Jones L, Pickering L, Sumnall H, McVeigh J, Bellis MA. Optimal provision of needle and syringe programmes for injecting drug users: a systematic review. Int J Drug Policy. 2010;21:335–42.PubMedCrossRef
33.
go back to reference MacArthur GJ, Minozzi S, Martin N, Vickerman P, Deren S, Bruneau J, et al. Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ. 2012;345:1–16.CrossRef MacArthur GJ, Minozzi S, Martin N, Vickerman P, Deren S, Bruneau J, et al. Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ. 2012;345:1–16.CrossRef
34.
go back to reference Platt L, Minozzi S, Reed J, Vickerman P, Hagan H, French C, et al. Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. Cochrane Database Syst Rev. 2017;9:Cd012021.PubMed Platt L, Minozzi S, Reed J, Vickerman P, Hagan H, French C, et al. Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. Cochrane Database Syst Rev. 2017;9:Cd012021.PubMed
35.
go back to reference Prendergast ML, Urada D, Podus D. Meta-analysis of HIV risk-reduction interventions within drug abuse treatment programs. J Consult Clin Psychol. 2001;69:389–405.PubMedCrossRef Prendergast ML, Urada D, Podus D. Meta-analysis of HIV risk-reduction interventions within drug abuse treatment programs. J Consult Clin Psychol. 2001;69:389–405.PubMedCrossRef
36.
go back to reference Sacks-Davis R, Horyniak D, Grebely J, Hellard M. Behavioural interventions for preventing hepatitis C infection in people who inject drugs: a global systematic review. Int J Drug Policy. 2012;23:176–84.PubMedCrossRef Sacks-Davis R, Horyniak D, Grebely J, Hellard M. Behavioural interventions for preventing hepatitis C infection in people who inject drugs: a global systematic review. Int J Drug Policy. 2012;23:176–84.PubMedCrossRef
37.
go back to reference Vold JH, Aas C, Leiva RA, Vickerman P, Chalabianloo F, Loberg EM, et al. Integrated care of severe infectious diseases to people with substance use disorders; a systematic review. BMC Infect Dis. 2019;19:306.PubMedPubMedCentralCrossRef Vold JH, Aas C, Leiva RA, Vickerman P, Chalabianloo F, Loberg EM, et al. Integrated care of severe infectious diseases to people with substance use disorders; a systematic review. BMC Infect Dis. 2019;19:306.PubMedPubMedCentralCrossRef
38.
go back to reference Weissman J, Kanamori M, Devieux JG, Trepka MJ, De La Rosa M. HIV risk reduction interventions among substance-abusing reproductive-age women: a systematic review. AIDS Educ Prev. 2017;29:121–40.PubMedPubMedCentralCrossRef Weissman J, Kanamori M, Devieux JG, Trepka MJ, De La Rosa M. HIV risk reduction interventions among substance-abusing reproductive-age women: a systematic review. AIDS Educ Prev. 2017;29:121–40.PubMedPubMedCentralCrossRef
39.
go back to reference Wright NM, Tompkins CN. A review of the evidence for the effectiveness of primary prevention interventions for hepatitis C among injecting drug users. Harm Reduct J. 2006;3:27.PubMedPubMedCentralCrossRef Wright NM, Tompkins CN. A review of the evidence for the effectiveness of primary prevention interventions for hepatitis C among injecting drug users. Harm Reduct J. 2006;3:27.PubMedPubMedCentralCrossRef
40.
go back to reference Haldane V, Cervero-Liceras F, Chuah FL, Ong SE, Murphy G, Sigfrid L, et al. Integrating HIV and substance use services: a systematic review. J Int AIDS Soc. 2017;20:21585.PubMedPubMedCentralCrossRef Haldane V, Cervero-Liceras F, Chuah FL, Ong SE, Murphy G, Sigfrid L, et al. Integrating HIV and substance use services: a systematic review. J Int AIDS Soc. 2017;20:21585.PubMedPubMedCentralCrossRef
41.
go back to reference Oldfield BJ, Muñoz N, McGovern MP, Funaro M, Villanueva M, Tetrault JM, et al. Integration of care for HIV and opioid use disorder. AIDS. 2019;33:873–84.PubMedCrossRef Oldfield BJ, Muñoz N, McGovern MP, Funaro M, Villanueva M, Tetrault JM, et al. Integration of care for HIV and opioid use disorder. AIDS. 2019;33:873–84.PubMedCrossRef
42.
go back to reference Meader N, Li R, Des Jarlais DC, Pilling S. Psychosocial interventions for reducing injection and sexual risk behaviour for preventing HIV in drug users. Cochrane Database Syst Rev. 2010;2010(1):CD007192.PubMedCentral Meader N, Li R, Des Jarlais DC, Pilling S. Psychosocial interventions for reducing injection and sexual risk behaviour for preventing HIV in drug users. Cochrane Database Syst Rev. 2010;2010(1):CD007192.PubMedCentral
43.
go back to reference Low AJ, Mburu G, Welton NJ, May MT, Davies CF, French C, et al. Impact of opioid substitution therapy on antiretroviral therapy outcomes: a systematic review and meta-analysis. Clin Infect Dis. 2016;63:1094–104.PubMedPubMedCentralCrossRef Low AJ, Mburu G, Welton NJ, May MT, Davies CF, French C, et al. Impact of opioid substitution therapy on antiretroviral therapy outcomes: a systematic review and meta-analysis. Clin Infect Dis. 2016;63:1094–104.PubMedPubMedCentralCrossRef
44.
go back to reference Hajarizadeh B, Cunningham EB, Reid H, Law M, Dore GJ, Grebely J. Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2018;3:754–67.PubMedCrossRef Hajarizadeh B, Cunningham EB, Reid H, Law M, Dore GJ, Grebely J. Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2018;3:754–67.PubMedCrossRef
45.
go back to reference Walsh N, Verster A, Rodolph M, Akl EA. WHO guidance on the prevention of viral hepatitis B and C among people who inject drugs. Int J Drug Policy. 2014;25:363–71.PubMedCrossRef Walsh N, Verster A, Rodolph M, Akl EA. WHO guidance on the prevention of viral hepatitis B and C among people who inject drugs. Int J Drug Policy. 2014;25:363–71.PubMedCrossRef
46.
go back to reference Bougioukas KI, Liakos A, Tsapas A, Ntzani E, Haidich A-B. Preferred reporting items for overviews of systematic reviews including harms checklist: a pilot tool to be used for balanced reporting of benefits and harms. J Clin Epidemiol. 2018;93:9–24.PubMedCrossRef Bougioukas KI, Liakos A, Tsapas A, Ntzani E, Haidich A-B. Preferred reporting items for overviews of systematic reviews including harms checklist: a pilot tool to be used for balanced reporting of benefits and harms. J Clin Epidemiol. 2018;93:9–24.PubMedCrossRef
47.
48.
go back to reference Becker L, Oxman A. Chapter 22: Overviews of reviews. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 510 (updated March 2011): The Cochrane Collaboration; 2011. Available: www.cochrane-handbook.org. Becker L, Oxman A. Chapter 22: Overviews of reviews. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 510 (updated March 2011): The Cochrane Collaboration; 2011. Available: www.​cochrane-handbook.​org.
49.
go back to reference Aromataris E, Fernandez R, Godfrey C, Holly C, Khalil H, Tungpunkom P. The Joanna Briggs Institute reviewers’ manual 2014: methodology for JBI umbrella reviews. Adelaide: University of Adelaide: Joanna Briggs Institute; 2014. Aromataris E, Fernandez R, Godfrey C, Holly C, Khalil H, Tungpunkom P. The Joanna Briggs Institute reviewers’ manual 2014: methodology for JBI umbrella reviews. Adelaide: University of Adelaide: Joanna Briggs Institute; 2014.
50.
go back to reference Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.PubMedPubMedCentralCrossRef Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.PubMedPubMedCentralCrossRef
51.
go back to reference Association AP. Diagnostic and statistical manual of mental disorders (DSM-5®). Arlington: American Psychiatric Pub; 2013. Association AP. Diagnostic and statistical manual of mental disorders (DSM-5®). Arlington: American Psychiatric Pub; 2013.
52.
go back to reference Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008.PubMedPubMedCentralCrossRef Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008.PubMedPubMedCentralCrossRef
53.
go back to reference Ellis S, Barnett-Page E, Morgan A, Taylor L, Walters R, Goodrich J. HIV prevention: a review of reviews assessing the effectiveness of interventions to reduce the risk of sexual transmission. London: Health Development Agency; 2003. Ellis S, Barnett-Page E, Morgan A, Taylor L, Walters R, Goodrich J. HIV prevention: a review of reviews assessing the effectiveness of interventions to reduce the risk of sexual transmission. London: Health Development Agency; 2003.
54.
go back to reference Palmateer N, Kimber J, Hickman M, Hutchinson S, Rhodes T, Goldberg D. Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews. Addiction. 2010;105:844–59.PubMedCrossRef Palmateer N, Kimber J, Hickman M, Hutchinson S, Rhodes T, Goldberg D. Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews. Addiction. 2010;105:844–59.PubMedCrossRef
Metadata
Title
Effectiveness of interventions for prevention of common infections in people who use opioids: a protocol for a systematic review of systematic reviews
Authors
Irina Kudrina
Svetlana Puzhko
Kristian B. Filion
Genevieve Gore
Elena Paraskevopoulos
Sarah Windle
Marc O. Martel
Mark J. Eisenberg
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Systematic Reviews / Issue 1/2021
Electronic ISSN: 2046-4053
DOI
https://doi.org/10.1186/s13643-021-01852-w

Other articles of this Issue 1/2021

Systematic Reviews 1/2021 Go to the issue